Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 369,662
  • Shares Outstanding, K 254,939
  • Annual Sales, $ 130 K
  • Annual Income, $ -234,630 K
  • 60-Month Beta -0.52
  • Price/Sales 2,875.11
  • Price/Cash Flow N/A
  • Price/Book 0.66
Trade LYEL with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 93.49%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.23
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1950 +21.34%
on 08/14/24
1.6950 -14.45%
on 07/31/24
-0.1300 (-8.23%)
since 07/30/24
3-Month
1.1800 +22.88%
on 06/27/24
2.8000 -48.21%
on 06/03/24
-1.2100 (-45.49%)
since 05/30/24
52-Week
1.1800 +22.88%
on 06/27/24
3.2556 -55.46%
on 03/04/24
-0.8600 (-37.23%)
since 08/29/23

Most Recent Stories

More News
Lyell Immunopharma: Q2 Earnings Snapshot

Lyell Immunopharma: Q2 Earnings Snapshot

LYEL : 1.4500 (-0.68%)
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

/PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy...

LYEL : 1.4500 (-0.68%)
Why Shares of Lyell Immunopharma Jumped This Week

The company gave a presentation regarding its lead therapy to treat solid tumors.

GS : 510.25 (+0.62%)
LYEL : 1.4500 (-0.68%)
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple...

LYEL : 1.4500 (-0.68%)
Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company...

LYEL : 1.4500 (-0.68%)
Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the...

LYEL : 1.4500 (-0.68%)
Lyell Immunopharma to Present Preclinical Data for Two Product Candidates in Clinical Development at ASGCT Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the...

LYEL : 1.4500 (-0.68%)
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipelineClinical...

LYEL : 1.4500 (-0.68%)
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March ...

LYEL : 1.4500 (-0.68%)
Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the...

LYEL : 1.4500 (-0.68%)

Business Summary

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 1.5733
2nd Resistance Point 1.5367
1st Resistance Point 1.4933
Last Price 1.4500
1st Support Level 1.4133
2nd Support Level 1.3767
3rd Support Level 1.3333

See More

52-Week High 3.2556
Fibonacci 61.8% 2.4627
Fibonacci 50% 2.2178
Fibonacci 38.2% 1.9729
Last Price 1.4500
52-Week Low 1.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar